Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of venglustat versus Cerezyme in adults and adolescents with type 3 Gaucher disease stable after enzyme replacement therapy
CTR20221236Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venglustat in Gaucher disease type 3, sponsored by Sanofi. Started Sep 2022; status: active.
02
Drugs
venglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on CTR20221236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221236.